蛋白质组学在感染性疾病研究中的应用

蛋白质组学在人类疾病研究中的应用 ,主要是通过比较分析正常组织细胞与异常组织细胞、同一疾病在不同的发展时期细胞内整体蛋白质的表达差异 ,对差异表达的蛋白质进行鉴定、定量、表征 ,寻找与疾病相关的新的标志物 ,为人类疾病研究提供新的手段和依据 ,蛋白质组学在感染性疾病研究中的应用就是其中的一个方面。1 .蛋白质组学在感染性疾病研究中的应用蛋白质组学在人类感染性疾病研究中的应用主要是对引起感染性疾病的致病源的整体蛋白质进行研究 ,同时结合血清学 ,对其进行分析 ,鉴定出与疾病相关的新的标志物 ,为感染性疾病的诊断、治疗…     

非酒精性脂肪性肝病蛋白质组学研究进展

非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)是一种常见慢性肝脏疾病,其发病率呈逐年上升趋势,但发病机制尚未明确,诊疗手段仍不完善.蛋白质组学(proteomics)的出现使NAFLD研究有了进一步的发展,相关研究已达21个.目前,蛋白质组学技术可以研究疾病相关的分子改变,从而寻找新的生物标志物和治疗靶标.在此,对蛋白质组学在NAFLD诊断及分期、发病机制和其他相关领域研究进展作一个较为全面的综述.首先,对研究中遇到的研究对象、样本种类、实验方法和标志物特征选择进行经验性总结.其次,除了介绍如何运用蛋白质组学研究病因、危险因素和重要分子在NAFLD发病机制中的作用,还介绍NAFLD发病机制的亚细胞蛋白质组学、修饰蛋白质组学以及蛋白质组学与转录组学相结合的研究实例.此外,对差异蛋白质的分析策略和价值作了重点阐述,收集到一些有望成为NAFLD治疗靶标的候选分子.最后,结合新技术展望研究新空间,以期能够有助于推动蛋白质组学在寻找新的疾病标志物、探索疾病分子机制和治疗靶标中开辟新的途径.     

糖尿病肾病蛋白质组学研究进展

糖尿病肾病(diabetic kidney disease, DKD)是糖尿病的主要并发症之一,严重威胁人类健康与生命.截至目前, DKD的致病机制尚未阐释清楚,且临床常用诊断方法的灵敏性和准确性并不十分理想,从而导致DKD确诊后治疗方案的确定比一般性肾脏疾病更为棘手.蛋白质作为生命活动的主要承担者与体现者,直接参与和调控各种生命过程.从蛋白质组学水平开展DKD研究,能够从整体、动态、互作网络等视角探究该疾病相关分子机制.针对不同生理病理条件下的DKD临床样本开展蛋白质组学研究,可全面探查与DKD显著相关的关键蛋白质;通过对这些蛋白质进行深入分析和验证,能够更直观地理解DKD发生发展的分子机制,并获得DKD进程相关候选标志物和后续疾病的潜在治疗靶点,为DKD的早期诊断和治疗新方法的探究奠定基础.近年来,随着蛋白质组学技术的不断发展,在蛋白质分离、质谱鉴定、生物信息学分析等蛋白质组学核心技术基础上衍生出了许多新兴技术,进一步推动了蛋白质组学在疾病生物标志物筛选、致病分子机制揭示、药物作用蛋白质靶点等研究中的应用.本文基于蛋白质组学研究技术,主要从DKD致病机制研究、早期诊断潜在生物标志物筛选、治疗靶点及效果评估三个方面对蛋白质组学在DKD研究中的应用进展进行了系统性综述.尽管蛋白质组学在DKD研究中取得了长足的进步,但仍具有较大的发展空间,特别是现已识别的大量潜在DKD分子标志物的相关性分析、药物蛋白质作用靶点临床验证与应用将是DKD未来研究的重点.     

蛋白质组学在肝病研究中的应用

蛋白质组学已被广泛应用于疾病相关研究. 综述了最近几年来蛋白质组学在肝脏疾病研究中特别是肝脏肿瘤、肝硬化、毒/药物肝损伤等方面的进展, 其研究结果将对生物标记物和药靶的寻找, 以及致病机理的阐述具有重要意义.     

蛋白质组学在结核分枝杆菌研究中的应用

蛋白质组学是在基因组学基础上发展起来的新兴学科, 其基本技术包括样品制备、蛋白质分离和蛋白质鉴定分析, 其中的核心技术是双向凝胶电泳技术(2-Dimensional Electrophoresis, 2-DE)和质谱技术(Mass Spectrometry, MS)。近年来, 蛋白质组学技术已应用于结核分枝杆菌的研究领域。应用蛋白质组学技术分离、鉴定、检测结核分枝杆菌致病株的全菌蛋白及分泌蛋白, 分析其蛋白组成, 可深入解析结核分枝杆菌的致病机理和耐药机制。通过对结核分枝杆菌致病株抗原的分析, 为研制预防结核病的新型疫苗拓展了空间。通过对结核分枝杆菌临床分离株的蛋白组成分析还发现了一些有意义的结核病早期诊断标志物。蛋白质组学技术还应用于寻找新的药物靶标, 在研制和筛选新的抗结核药物等方面展示了一些有价值的研究成果, 为更好地开展结核病的预防、早期诊断及治疗打下了基础。     

病毒感染蛋白质组学研究进展

病毒的侵入会导致宿主细胞蛋白表达模式的改变,这种改变将影响宿主细胞的正常生理功能并决定病毒的致病进程和结果.因此,病毒感染蛋白质组学研究有助于揭示病毒与宿主的相互作用机制和病毒的分子致病机制,以及寻找病毒早期感染的分子标记、建立早期诊断方法、评价治疗效果和预后.本文介绍了病毒感染蛋白质组学研究技术、病毒诱导宿主细胞蛋白质组改变和病毒感染宿主血清差异蛋白质组等方面的研究进展.     

尿蛋白质组学在疾病标志物研究中的应用

尿液是重要的疾病标志物来源. 本文介绍了当前尿蛋白质组学的研究进展和尿液中疾病标志物研究的主要问题, 并对未来的发展进行了展望. 由于实际的临床问题通常是对症状相似的多种疾病进行鉴别诊断, 仅仅比较某一种疾病组和健康人对照组的尿蛋白质组差异不足以找到具有诊断能力的标志物. 另外, 尿蛋白质组在个体间和同一个体的不同生理条件下的变化也为疾病标志物的寻找带来了困难. 本文提出, 进行正常人群个体间和不同生理条件下尿蛋白质变化范围的研究可以为鉴定疾病标志物提供参考标准, 从而帮助研究者发现由疾病、而不是生理学差异引起的蛋白的变化. 比较蛋白在血浆和尿液中丰度的变化可以揭示肾脏的生理学功能和发现疾病标志物. 最后提出, 建立一个数据共享平台, 收集和整合已有的疾病标志物研发成果, 将大大推动尿蛋白质组研究的发展.     

污染胁迫下的蚯蚓蛋白质组学研究进展

随着蛋白质组学的发展和每年有大量环境污染物进入土壤环境中,污染胁迫模式动物的相关生物标志物受到日益关注。蚯蚓,作为土壤中最大的无脊椎动物,是研究和评价土壤生态污染良好的模式动物。研究蚯蚓的蛋白质组学,对于寻找环境生态污染相关生物标志物和阐明生态毒理学机制有着十分重要的现实意义。目前已知的污染胁迫下蚯蚓蛋白质组学研究,提供了几个特定污染物胁迫蚯蚓的蛋白表达谱。这些蛋白涉及许多生物学过程,例如信号传导、糖酵解、能量代谢、分子伴侣和转录调节,提示了相关污染物可能的生态毒理学机制,有望成为潜在的生物标志物,用于有毒污染物的监测,但其特异性需要进一步试验的验证。对蚯蚓受污染胁迫的蛋白质组表达谱及潜在生物标志物进行简要综述。     

蛋白质组学在妊娠期高血压疾病中的研究进展

蛋白质组学的兴起能快速筛选并鉴定疾病的特异性生物标志物,有助于研究妊娠期高血压疾病的病因、发生机制,通过特异性生物标志物进行早期诊断,从而改善母儿结局,降低母儿严重发病率和死亡率。本文综述近年来与妊娠期高血压疾病相关的蛋白质研究及其在妊娠期高血压疾病患者血液、脑脊液、尿液、羊水、滋养细胞中差异蛋白质谱的分析,为进一步研究提供思路。     

基于蛋白质组学技术的新型冠状病毒肺炎研究进展

新型冠状病毒肺炎（coronavirus disease 2019，COVID-19）是一种由严重急性呼吸系统综合征冠状病毒2（severe acute respiratory syndrome coronavirus 2，SARS-CoV-2）引发的传染病。此种病毒传染性强、传播速度快，对全球人民的身体健康和生命安全造成严重威胁。蛋白质组学技术以其高通量、高灵敏度的特点，在疾病生物标志物的发现、分子机制研究及治疗靶点研究中扮演着重要角色，并被广泛应用于COVID-19的研究中。本文介绍了SARS-CoV-2的基因组结构及病毒感染过程，总结了目前常用的基于质谱的蛋白质组学研究技术，重点综述了蛋白质组学技术在COVID-19生物标志物的发现、分子机制研究和药物治疗靶标研究中的应用进展，最后展望了蛋白质组学的未来发展方向，以期能够有助于推动蛋白质组学技术在COVID-19精准诊断和治疗中的发展。     

病毒蛋白质组学及其应用

病毒蛋白质组学是蛋白质组学研究技术在病毒学领域的应用,其研究方法主要是基于质谱鉴定的电泳分离或色谱分离技术。病毒蛋白质组学的研究可以补充基因组注释、纯化单一的病毒成分、研究病毒与其宿主细胞蛋白的相互作用、识别病毒作用的靶位点、鉴定病毒感染的致病因子及病毒的进化关系、识别病毒的免疫源性蛋白。病毒蛋白质组的研究有助于对病毒致病性的了解,加速新的诊断方法及治疗药物的研制,增强对病毒的生物防御。由于一些技术及主观因素的影响,病毒蛋白质组的研究是很有限的,这是一个亟待重视并增强的领域。     

Proteomics in biomarker discovery and drug development

Proteomics is a research field aiming to characterize molecular and cellular dynamics in protein expression and function on a global level. The introduction of proteomics has been greatly broadening our view and accelerating our path in various medical researches. The most significant advantage of proteomics is its ability to examine a whole proteome or sub-proteome in a single experiment so that the protein alterations corresponding to a pathological or biochemical condition at a given time can be considered in an integrated way. Proteomic technology has been extensively used to tackle a wide variety of medical subjects including biomarker discovery and drug development. By complement with other new technique advances in genomics and bioinformatics, proteomics has a great potential to make considerable contribution to biomarker identification and to revolutionize drug development process. This article provides a brief overview of the proteomic technologies and their application in biomarker discovery and drug development.     

Discovery and Validation of Clinical Biomarkers of Cancer: A Review Combining Metabolomics and Proteomics

Early detection and diagnosis of cancer can allow timely medical intervention, which greatly improves chances of survival and enhances quality of life. Biomarkers play an important role in assisting clinicians and health care providers in cancer diagnosis and treatment follow‐up. In spite of years of research and the discovery of thousands of candidate cancer biomarkers, only a few have transitioned to routine usage in the clinic. This review highlights advances in proteomics technologies that have enabled high rates of discovery of candidate cancer biomarkers and evaluates integration with other omics technologies to improve their progress through to validation and clinical translation. Furthermore, it gauges the role of metabolomics technology in cancer biomarker research and assesses it as a complementary tool in aiding cancer biomarker discovery and validation.     

From Proteomics Research To Clinical Practice

The third International Conference of the Hellenic Proteomics Society, From Proteomics Research to Clinical Practice, took place in Nafplio (Greece), from 30 March to 1 April 2009. This year the conference was dedicated to the application of proteomics in clinical practice. Many scientists from different European counties participated in the conference, which made this event unique in the field of proteomics for the southeastern region of Europe. Extensive presentations and discussions covered nearly every aspect of the modern point of view regarding the application of proteomics in various diseases, the quantitative peptidomics and proteomics approaches, and the advances of methodologies for biomarker discovery and validation.     

Targeted and Untargeted Proteomics Approaches in Biomarker Development

An enormous amount of research effort has been devoted to biomarker discovery and validation. With the completion of the human genome, proteomics is now playing an increasing role in this search for new and better biomarkers. Here, what leads to successful biomarker development is reviewed and how these features may be applied in the context of proteomic biomarker research is considered. The “fit‐for‐purpose” approach to biomarker development suggests that untargeted proteomic approaches may be better suited for early stages of biomarker discovery, while targeted approaches are preferred for validation and implementation. A systematic screening of published biomarker articles using MS‐based proteomics reveals that while both targeted and untargeted technologies are used in proteomic biomarker development, most researchers do not combine these approaches. i) The reasons for this discrepancy, (ii) how proteomic technologies can overcome technical challenges that seem to limit their translation into the clinic, and (iii) how MS can improve, complement, or replace existing clinically important assays in the future are discussed.     

Targeted proteomics: a bridge between discovery and validation

New technologies in mass spectrometry are beginning to mature and show unique advantages for the identification and quantitation of proteins. In recent years, one of the significant goals of clinical proteomics has been to identify biomarkers that can be used for clinical diagnosis. As technology has progressed, the list of potential biomarkers has grown. However, the verification and validation of these potential biomarkers is increasingly challenging and require high-throughput quantitative assays, targeting specific candidates. Targeted proteomics bridges the gap between biomarker discovery and the development of clinically applicable biomarker assays.     

Targeted Proteomics for Studying Pathogenic Bacteria

Mass spectrometry‐based proteomics has been extensively used to map bacterial proteomes, which has led to a better understanding of the molecular mechanisms underlying bacterial infection and bacteria–host interactions. Quantitative proteomics using selected or parallel reaction monitoring is considered one of the most sensitive and specific quantitative MS‐based approaches and has significantly advanced proteome studies of pathogenic bacteria. Here, recent applications of targeted proteomics for bacteria identification, biomarker discovery, and the characterization of bacterial virulence and antimicrobial resistance are reviewed among others. Results of such studies are expected to further contribute to improve the fight against the most common human pathogenic bacteria.     

Proteomics applications in prion biology and structure

Prion diseases are a heterogeneous class of fatal neurodegenerative disorders associated with misfolding of host cellular prion protein (PrP^C) into a pathological isoform, termed PrP^Sc. Prion diseases affect various mammals, including humans, and effective treatments are not available. Prion diseases are distinguished from other protein misfolding disorders – such as Alzheimer’s or Parkinson’s disease – in that they are infectious. Prion diseases occur sporadically without any known exposure to infected material, and hereditary cases resulting from rare mutations in the prion protein have also been documented. The mechanistic underpinnings of prion and other neurodegenerative disorders remain poorly understood. Various proteomics techniques have been instrumental in early PrP^Sc detection, biomarker discovery, elucidation of PrP^Sc structure and mapping of biochemical pathways affected by pathogenesis. Moving forward, proteomics approaches will likely become more integrated into the clinical and research settings for the rapid diagnosis and characterization of prion pathogenesis.     

Proteomics and its applications for biomarker discovery in human saliva

Human saliva is a biological fluid with enormous diagnostic potential. Because saliva can be non-invasively collected, it provides an attractive alternative for blood, serum or plasma. It has been postulated that the blood concentrations of many components are reflected in saliva. Saliva harbors a wide array of proteins, which can be informative for the detection of diseases. Profiling the proteins in saliva over the course of disease progression could reveal potential biomarkers indicative of different stages of diseases, which may be useful in medical diagnostics. With advanced instrumentation and developed refined analytical techniques, proteomics is widely envisioned as a useful and powerful approach for salivary proteomic biomarker discovery. As proteomic technologies continue to mature, salivary proteomics have great potential for biomarker research and clinical applications. The progress and current status of salivary proteomics and its application in the biomarker discovery of oral and systematic diseases will be reviewed. The scientific and clinical challenges underlying this approach will also be discussed.